Forge A Successful CRISPR Therapeutic Path With High-Quality GMP sgRNA
Source: Synthego Corporation
The rapid increase in CRISPR-mediated cell and gene therapies in clinical trials over the past few years is a testimony to the promising future of next-generation medicine.
While improved technological prowess empowers the development of more CRISPR-edited therapies, supply-chain and manufacturing hurdles still pose significant barriers to clinical and commercialization timelines.
In this webinar, Synthego's Robert Deans, Chief Scientific Officer and Beckinam Nowatzke, Senior Director of Quality & Regulatory will elaborate on our preclinical and GMP offerings that support CRISPR therapy developers and accelerate time to clinic.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Synthego Corporation
This website uses cookies to ensure you get the best experience on our website. Learn more